CompletedNot Applicable

Role of Monocytes Sub-populations in Thrombosis Associated With Myeloproliferative Neoplasms (MonSThr)

France68 participantsStarted 2022-10-05

Plain-language summary

Myeloproliferative neoplasms (MPN) are hematological malignancies associated with a major risk of thrombosis. Monocytes are hematopoietic cells with a central role in thrombosis. An activation of monocytes has been demonstrated in MPN patients. However, their study in MPN and their thrombotic complications has never been performed. In this study, we aim to evaluate the association between monocytes sub-populations and thrombotic risk in MPN patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults patients (age ≥ 18 years) * Inclusion at diagnosis or during the year following the diagnosis of PV or ET (2016 WHO criteria except bone marrow biopsy that is optional in the presence of a marker of clonality) * Subject registered with a social security scheme * Written informed consent obtained Exclusion Criteria: * Patients with cytoreductive treatment (hydroxyurea, anagrelide, interferon, ruxolitinib) at the time of blood sampling * Chronic inflammatory disease (cancer, vasculitis, rheumatism, hepato-gastro-intestinal diseases). * Long term anti-inflammatory treatments: * Corticoids * Nonsteroidal anti-inflammatory drugs * Aspirin (\> 325 mg per day) * Cyclo-oxygenase II inhibitors * Persons under judicial safeguards, trustee or curatorship * Person unable to give her consent * Non-cooperative person * Exclusion period after another clinical study or participation to another clinical study in the 30 days before inclusion

What they're measuring

History of thrombosis

Timeframe: At inclusion, up to 1 year after diagnosis

Trial details

NCT IDNCT05419648

SponsorUniversity Hospital, Bordeaux

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-07-22